I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 9 studies | 21% ± 5% | |
| CD8-positive, alpha-beta T cell | 9 studies | 19% ± 4% | |
| B cell | 7 studies | 20% ± 4% | |
| CD4-positive, alpha-beta T cell | 7 studies | 20% ± 4% | |
| regulatory T cell | 7 studies | 18% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 6 studies | 21% ± 6% | |
| CD8-positive, alpha-beta memory T cell | 6 studies | 20% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 20% ± 3% | |
| T cell | 4 studies | 17% ± 2% | |
| naive B cell | 4 studies | 20% ± 4% | |
| effector memory CD8-positive, alpha-beta T cell | 4 studies | 21% ± 7% | |
| epithelial cell | 4 studies | 24% ± 6% | |
| gamma-delta T cell | 4 studies | 26% ± 9% | |
| plasmablast | 3 studies | 39% ± 13% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 18% ± 3% | |
| hematopoietic precursor cell | 3 studies | 19% ± 4% | |
| glutamatergic neuron | 3 studies | 27% ± 4% | |
| transit amplifying cell | 3 studies | 23% ± 7% | |
| mature NK T cell | 3 studies | 17% ± 1% |
